Evaluation of Biodistribution and Safety of Adenovirus Vectors Containing Group B Fibers After Intravenous Injection into Baboons
- 1 June 2005
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 16 (6) , 664-677
- https://doi.org/10.1089/hum.2005.16.664
Abstract
Vectors containing group B adenovirus (Ad) fibers are able to efficiently transduce gene therapy targets that are refractory to infection with standard Ad serotype 5 (Ad5) vectors, including malignant tumor cells, hematopoietic stem cells, and dendritic cells. Preliminary studies in mice indicate that, after intravenous injection, B-group fiber-containing Ads do not efficiently transduce most organs and cause less acute toxicity than Ad5 vectors. However, biodistribution and safety studies in mice are of limited value because the mouse analog of the B-group Ad receptor, CD46, is expressed only in the testis, whereas in humans, CD46 is expressed on all nucleated cells. Unlike mice, baboons have CD46 expression patterns and levels that closely mimic those in humans. We conducted a biodistribution and toxicity study of group B Ad fiber-containing vectors in baboons. Animals received phosphate-buffered saline, Ad5-bGal (a first-generation Ad5 vector), or B-group fiber-containing Ads (Ad5/35-bGal and Ad5/11-bGal) at a dose of 2 × 1012 VP/kg, and vector biodistribution and safety was analyzed over 3 days. The amount of Ad5/35-bGal and Ad5/11-bGal vector genomes was in most tissues one to three orders of magnitude below that of Ad5. Significant Ad5/35- and Ad5/11-mediated transgene (β-galactosidase) expression was seen only in the marginal zone of splenic follicles. Compared with the animal that received Ad5-bGal, all animals injected with B-group fiber-containing Ad vectors had lower elevations in serum proinflammatory cytokine levels. Gross and histopathology were normal in animals that received B-group Ad fiber-containing Ads, in contrast to the Ad5-infused animal, which showed widespread endothelial damage and inflammation. In a further study, a chimeric Ad5/35 vector carrying proapoptotic TRAIL and Ad E1A genes under tumor-specific regulation was well tolerated in a 30-day toxicity study. No major clinical, serologic, or pathologic abnormalities were noticed in this animal.Keywords
This publication has 64 references indexed in Scilit:
- Four Viruses, Two Bacteria, and One Receptor: Membrane Cofactor Protein (CD46) as Pathogens' MagnetJournal of Virology, 2004
- A Tumor-Targeted and Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL for Treatment of Liver MetastasesMolecular Therapy, 2004
- Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus ImmunityJournal of Virology, 2003
- A New Type of Adenovirus Vector That Utilizes Homologous Recombination To Achieve Tumor-Specific ReplicationJournal of Virology, 2002
- Targeting and Hematopoietic Suppression of Human CD34+Cells by Measles VirusJournal of Virology, 2002
- Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell–induced inflammationNature Immunology, 2002
- Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of DiseaseJournal of Virology, 2002
- Lethal Toxicity, Severe Endothelial Injury, and a Threshold Effect with High Doses of an Adenoviral Vector in BaboonsHuman Gene Therapy, 2002
- A Capsid-Modified Adenovirus Vector Devoid of All Viral Genes: Assessment of Transduction and Toxicity in Human Hematopoietic CellsMolecular Therapy, 2001
- Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassayClinical and Experimental Immunology, 1991